Impact of balloon predilatation in patients with reduced versus preserved ejection fraction during transcatheter aortic valve implantation

医学 射血分数 内科学 心脏病学 气球 心力衰竭
作者
Heba M. El-Naggar,Wolfgang Schoels,Marwan S. Mahmoud,Yehia T. Kishk,Matthias Kullmer,Mohamad Dia,Magdy Algowhary
出处
期刊:Asian Cardiovascular and Thoracic Annals [SAGE Publishing]
卷期号:30 (9): 985-991
标识
DOI:10.1177/02184923221126086
摘要

Background Although there is a trend toward direct transcatheter aortic valve implantation (TAVI), still balloon predilatation is necessary in some cases, especially in patients with severe calcification. However, predilatation including rapid ventricular pacing may have adverse outcomes, especially in patients with reduced ejection factor (EF). Objective To evaluate the impact of predilatation on in-hospital outcomes in patients with reduced versus preserved EF underwent TAVI. Methods This was a prospective observational study including 110 patients (72 patients with preserved EF (≥50%) and 38 patients with reduced EF (<50%)) who underwent TAVI. The two groups were compared regarding in-hospital outcomes. Results Predilatation was done routinely in all 110 patients. The mean age was significantly higher in patients with preserved EF (82.76 ± 5.74 vs. 80.13 ± 6.51 years; p = 0.03). The majority (51.4%) of patients with preserved EF were females but the majority (73.7%) of those with reduced EF were males ( P < 0.001). Predilatation showed no statistical difference regarding in-hospital mortality (2.6% vs. 1.4%; p = 0.29), hemodynamic instability (5.3% vs. 0.0%; p = 0.11), stroke (0% vs. 1.4%; p = 0.67), conduction defects (13.2% vs. 19.4%; p = 0.29), permanent pacemaker implantation (7.9% vs. 5.5%; p = 0.45), paravalvular leakage (5.3% vs. 2.8%; p = 0.42), vascular complications (7.9% vs. 11.1%; p = 0.43), and acute kidney injury (7.9% vs. 7%; p = 0.4) in patients with reduced versus preserved EF, respectively. Conclusion When balloon predilatation is inevitable during TAVI it is safe in patients with reduced as well as preserved EF with no added risk of hemodynamic instability or other outcomes.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
潇洒青荷发布了新的文献求助10
刚刚
刚刚
1秒前
Limerence完成签到,获得积分10
1秒前
flyingdragon完成签到,获得积分10
1秒前
超超完成签到,获得积分20
2秒前
Ceng完成签到,获得积分10
2秒前
2秒前
3秒前
笑点低的一一完成签到,获得积分10
3秒前
3秒前
复杂的觅波完成签到,获得积分10
3秒前
大个应助张春梦紫采纳,获得10
3秒前
Hello应助liqiang采纳,获得10
3秒前
4秒前
5秒前
xdf发布了新的文献求助10
6秒前
6秒前
6秒前
7秒前
7秒前
7秒前
丘比特应助笑点低的一一采纳,获得10
7秒前
英勇的吐司完成签到,获得积分10
7秒前
8秒前
8秒前
忧郁的梦琪完成签到,获得积分20
8秒前
CodeCraft应助中国大陆采纳,获得10
8秒前
Copyright应助sube采纳,获得10
9秒前
充电宝应助li_xiao_mu采纳,获得80
9秒前
从容的完成签到 ,获得积分10
9秒前
吱哦周发布了新的文献求助10
9秒前
无限的民完成签到,获得积分10
10秒前
11秒前
11秒前
壹叁发布了新的文献求助10
11秒前
Tomice发布了新的文献求助10
12秒前
liqiang完成签到,获得积分20
12秒前
mouse完成签到,获得积分10
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
University Physics for the Life Sciences 500
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6953943
求助须知:如何正确求助?哪些是违规求助? 8637786
关于积分的说明 18317294
捐赠科研通 6398044
什么是DOI,文献DOI怎么找? 3083051
关于科研通互助平台的介绍 2129007
邀请新用户注册赠送积分活动 2059872